Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




RNA Biomarker Assay Now Manufactured According to Strict ISO Regulatory Criteria

By LabMedica International staff writers
Posted on 19 Aug 2014
A line of diagnostic kits that measures RNA biomarkers with single-molecule sensitivity is now being manufactured under the stringent requirements of ISO 13485:2003 certification.

Advanced Cell Diagnostics, Inc. More...
(Hayward, CA, USA), a global technology and market leader in in situ nucleic acid detection for life science research and clinical diagnostics, announced that the production facility for its line of RNAscope assays has received ISO 13485:2003 certification. ISO 13485:2003 certification, issued by the International Organization for Standardization (Geneva, Switzerland), the world's largest developer and publisher of international standards, regulates design, development, production, and commercialization for the implementation of quality management systems and various other technical and operational procedures.

Radioscope technology is the first automated multiplex RNA in situ hybridization platform capable of detecting and quantifying RNA biomarkers with single-molecule sensitivity. RNA expression levels are highly dynamic and integrate both genetic and epigenetic mechanisms of gene regulation. Thus, RNA expression reflects the state of a biological system. Measuring RNA biomarkers as RNA provides the most direct route for biomarker validation and assay development.

RNAscope employs a proven design strategy similar to fluorescence resonance energy transfer (FRET), in which two independent probes (double Z probes) must hybridize to the target sequence in tandem in order for signal amplification to occur. Because it is highly unlikely that two independent probes will hybridize to a nonspecific target right next to each other, this design concept ensures selective amplification of target-specific signals. For each target RNA species, 20 double Z target probe pairs are designed to specifically hybridize to the target molecule, but not to nontargeted molecules.

"Advanced Cell Diagnostics' vision is to make RNAscope the PCR equivalent for in situ nucleic acid detection and drive adoption of this technology in diagnostic tests," said Dr.Yuling Luo, president and CEO of Advanced Cell Diagnostics. "This ISO certification is the first step in our quality systems road map, which is designed to ensure that we supply products of the highest quality to our customers and provide a seamless path for our partners to translate scientific advances to patient benefits."

Related Links:

Advanced Cell Diagnostics, Inc.
International Organization for Standardization



Gold Member
Hematology Analyzer
Medonic M32B
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Automatic CLIA Analyzer
Shine i9000
Gold Member
Hybrid Pipette
SWITCH
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.